Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyAmeriHealth omalizumab Prior Auth Coverage | OpenP…
    Ask Trek AI about this page
    CurrentAmeriHealthPolicy N/A

    Omalizumab (Xolair) prior authorization for allergic asthma and chronic urticaria

    Customize your policy alerts

    Sign up for all AmeriHealth policy alerts

    Know when AmeriHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Form and criteria governing prior authorization and delivery of omalizumab (Xolair) for patients with allergic asthma or chronic spontaneous urticaria; intended for prescribing physicians submitting requests to AmeriHealth.

    Policy Summary
    PayerAmeriHealth
    PolicyOmalizumab (Xolair) prior authorization for allergic asthma and chronic urticaria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionComplete and fax the prior authorization form with diagnosis (ICD-10), required clinical answers, baseline serum IgE (for allergic asthma) and a copy of the prescription.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2indications
    baseline serum IgEbaseline IgE required
    ≥4 weeksantihistamine trial

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥2 weeksalternative agent trials

    Coverage criteria for Omalizumab (Xolair)

    Allergic asthma (initial/continued therapy)

    Covered when ALL of the following are met

    Allergic asthma criteria: 1) Positive skin test or in vitro reactivity to a perennial aeroallergen (documented on form); 2) Patient has failed, is unresponsive to, or is inadequately controlled on high‑dose inhaled corticosteroids in combination with a long‑acting beta‑agonist (documented on form); 3) Baseline serum IgE level drawn prior to initiation of Xolair is provided with the request; plus diagnosis (ICD‑10) and a copy of the prescription are included.

    Baseline serum IgE must be drawn prior to initiation and faxed with the form; answers must be documented on the form.

    Chronic urticaria (initial/continued therapy)

    Covered when ALL of the following are met

    Chronic urticaria criteria: 1) Documented failure, contraindication, or intolerance to at least a 4‑week trial of a second‑generation non‑sedating H1 antihistamine (drug, dose, and duration must be listed on the form); 2) When applicable, documented failure, contraindication, or intolerance to at least a 2‑week trial of any checked alternative agents (leukotriene receptor antagonist; H2‑receptor antagonist; first‑generation H1 antihistamine; short‑term systemic glucocorticosteroids; substitution to a different second‑generation non‑sedating H1 antihistamine; or cyclosporine) with drug/dose/duration provided; plus diagnosis (ICD‑10) and a copy of the prescription are included.

    Trials and durations must be documented on the form; for allergic asthma items (prescription copy) also required.

    Requests that are not fully completed on the AmeriHealth prior authorization form will not be reviewed. The form collects patient and prescriber identifiers, diagnosis (including ICD‑10), and clinical responses required for each indication; missing any of these required elements may result in the request being returned without review.

    ONLY COMPLETED REQUESTS WILL BE REVIEWED. The form requires the requester to indicate whether this is a New start or Continued treatment before the submission will be considered.

    Codes and trial durations

    Form codemixed
    H18554Prior authorization / form indicator appearing throughout the document
    Second-generation non-sedating H1 antihistamine trial duration
    Required duration>= 4 weeks
    Example agentsSecond-generation non-sedating H1 antihistamines (e.g., cetirizine [Zyrtec], fexofenadine [Allegra], loratadine [Claritin])
    Dose requirementAt maximum recommended dose as stated on form
    Alternative agent trial duration (listed drugs)
    Required duration>= 2 weeks
    Listed alternative agentsLeukotriene receptor antagonist (e.g., montelukast [Singulair]); Histamine H2-receptor antagonist (e.g., famotidine [Pepcid], ranitidine [Zantac]); First‑generation (sedating) H1 antihistamine (e.g., diphenhydramine [Benadryl]); Short‑term systemic glucocorticosteroids; Substitution to a different second‑generation non‑sedating H1 antihistamine; Cyclosporine

    Provider requirements and actions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Complete and submit the prior authorization form indicating diagnosis (include ICD-10), whether this is a new start or continued treatment, and supporting clinical information. Only completed requests will be reviewed.

    • Check one: New start or Continued treatment
    • Include diagnosis with ICD-10 on the PA form
    • Attach supporting clinical documentation (see items below)
    Step Therapy

    Step Therapy Required for Chronic Urticaria

    For chronic urticaria, document failure, contraindication, or intolerance to a trial of a second-generation non-sedating H1 antihistamine at maximum recommended dose for at least 4 weeks (e.g., cetirizine, fexofenadine, loratadine). List the drug, dose and duration on the form.

    • At least one ≥4-week trial of a second-generation non-sedating H1 antihistamine at maximum recommended dose must be documented

    Background

    The form is intended to document eligibility for omalizumab (Xolair) in two clinical contexts: allergic asthma and chronic urticaria. For allergic asthma the form requests evidence of positive skin test or in vitro reactivity to a perennial aeroallergen, documentation of inadequate control on high‑dose inhaled corticosteroid plus a long‑acting beta‑agonist, and the patient’s baseline serum IgE drawn prior to initiation (to be faxed with the form). For chronic urticaria the form captures required prior antihistamine and alternative agent trials (including durations) and other documentation needed to support medical necessity.

    Key definitions

    Positive skin test or in vitro reactivity to a perennial aeroallergen
    DefinitionPositive skin test or in vitro reactivity to a perennial aeroallergen is documented by answering 'Yes' to the form question for allergic asthma.
    Requirement for allergic asthma criteriaA documented positive skin test or in vitro reactivity to a perennial aeroallergen is required for coverage consideration.
    Form actionProvider must indicate Yes/No on the prior authorization form (checkbox) and include supporting documentation as requested.
    Baseline serum IgE
    DefinitionBaseline serum IgE is the patient’s total serum IgE level measured prior to initiation of Xolair (omalizumab).
    Requirement for allergic asthmaBaseline serum IgE level must be drawn prior to initiation and provided with the prior authorization request (fax the level with the form).
    Policy Summary
    PayerAmeriHealth
    PolicyOmalizumab (Xolair) prior authorization for allergic asthma and chronic urticaria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionComplete and fax the prior authorization form with diagnosis (ICD-10), required clinical answers, baseline serum IgE (for allergic asthma) and a copy of the prescription.
    SourceLink
    On This Page
    Coverage criteria for Omalizumab (Xolair)Codes and trial durationsProvider requirements and actionsBackgroundKey definitions
    DocumentationCheck applicable agent(s) and list drug/dose/duration on form
  1. Provide drug name, dose, and duration
  2. Documentation Required

    Required Documentation

    A copy of the prescription must accompany the medication request for delivery. For allergic asthma, provide documentation of positive allergen testing (skin test or in vitro) and baseline serum IgE drawn prior to initiation; include the numeric IgE value on the form and fax the baseline IgE level. For chronic urticaria, include documentation of trials listed on the form (e.g., leukotriene receptor antagonist, H2 antagonist, first-generation H1, systemic glucocorticosteroids, substitution to a different second-generation H1, cyclosporine) as applicable. Include prescription quantity, refills, dosing instructions, and physician signature.

    • Attach copy of prescription for medication delivery
    • For allergic asthma: document allergen testing result (yes/no) and provide baseline serum IgE (IU/mL) drawn prior to initiation; fax IgE result
    • For chronic urticaria: document prior medication trials and provide drug/dose/duration for each checked item
    • Include quantity, number of refills, dosing instructions, and physician signature on the form
    Denial Risk

    Denial Risk — Missing or Incomplete Information

    Applications may be denied if required clinical questions or data are missing — for example: missing indication/ICD-10, missing start vs continuation indicator, no documentation of allergen testing for allergic asthma, absent baseline serum IgE, or lack of documentation of 4-week antihistamine trial for chronic urticaria. Ensure all checklist items on the form are completed to avoid denial.

    • Missing diagnosis or ICD-10 code
    • No indication whether request is new start or continuation
    • Absent baseline serum IgE for allergic asthma
    • No documentation of positive allergen testing when required
    • No documentation of ≥4-week second-generation H1 antihistamine trial for chronic urticaria
    Form fieldThe form requests the numeric IgE value in IU/mL and instructs to fax the baseline serum IgE level along with the form.